Published in Transpl Int on March 26, 2012
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients-A Prospective, Randomized Study. Transplantation (2015) 1.19
Is it time to give up with calcineurin inhibitors in kidney transplantation? World J Transplant (2013) 0.86
A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Transpl Int (2014) 0.80
The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation (2016) 0.79
A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk. J Korean Med Sci (2015) 0.75
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. J Transplant (2016) 0.75
Practical considerations for the use of mTOR inhibitors. Transplant Res (2015) 0.75
A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation. Ther Drug Monit (2017) 0.75
Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus. Am J Transplant (2017) 0.75
Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med (2007) 9.44
Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med (2008) 6.60
Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med (2016) 5.31
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med (2012) 2.98
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 2.33
C4d-positive interacinar capillaries correlates with donor-specific antibody-mediated rejection in pancreas allografts. Transplantation (2008) 2.04
12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int (2007) 2.03
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Analysis of endothelial precursor cells in chronic migraine: a case-control study. Cephalalgia (2012) 1.99
Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis (2009) 1.99
[Encephalitis due to antibodies against the NMDA receptor. A case report of a female patient with no associated tumour and a literature review]. Rev Neurol (2010) 1.98
Correlation between the protein/creatinine ratio in spot urine and 24-hour urine protein. Nefrologia (2012) 1.97
Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant (2005) 1.84
Kidneys from donors after cardiac death provide survival benefit. J Am Soc Nephrol (2010) 1.76
Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis (2010) 1.75
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73
Hepatitis E virus and neurologic disorders. Emerg Infect Dis (2011) 1.70
Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia (2012) 1.67
Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology (2013) 1.64
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int (2011) 1.53
Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis (2008) 1.53
An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation (2015) 1.52
Liver transplantation in Latin America: the state-of-the-art and future trends. Transplantation (2014) 1.49
Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant (2010) 1.48
Anti-human leukocyte antigen immunization after early allograft nephrectomy. Transplantation (2012) 1.47
Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. Clin J Am Soc Nephrol (2012) 1.46
The relationship between homocysteine and genes of folate-related enzymes in migraine patients. Headache (2009) 1.46
Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology (2010) 1.44
The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation (2004) 1.44
Frequent but late donor-directed antibody formation after kidney transplantectomy within one month after grafting. Transplantation (2006) 1.44
Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation (2010) 1.44
Program of laparoscopic living-donor nephrectomy with retroperitoneoscopic access - a Polish single-center experience - success or disappointment? Ann Transplant (2013) 1.43
A novel locus for familial migraine on Xp22. Headache (2010) 1.43
Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant (2007) 1.43
Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation (2007) 1.41
Occult hepatitis C virus infection in hemodialysis patients: examining the evidence. Am J Kidney Dis (2009) 1.39
Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients. Transplantation (2011) 1.39
Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev (2016) 1.39
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int (2004) 1.31
Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. Clin J Am Soc Nephrol (2011) 1.26
Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen. Clin Transplant (2008) 1.18
Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats. Diabetes (2003) 1.17
Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol (2010) 1.17
Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis (2004) 1.14
Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism culminating in motor neuron disease. Mov Disord (2004) 1.14
A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation (2003) 1.13
Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerg Infect Dis (2011) 1.13
Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections. Clin Vaccine Immunol (2009) 1.13
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation (2011) 1.13
Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant (2004) 1.11
Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes (2004) 1.11
Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother (2010) 1.10
Hepatitis E virus quasispecies and the outcome of acute hepatitis E in solid-organ transplant patients. J Virol (2012) 1.09
Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis (2004) 1.09
Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant (2005) 1.08
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol (2005) 1.06
The influence of obesity on short- and long-term graft and patient survival after renal transplantation. Transpl Int (2006) 1.06
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Oxalate nephropathy associated with chronic pancreatitis. Clin J Am Soc Nephrol (2011) 1.06
Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic Biol Med (2008) 1.05
Quality of life in chronic daily headache: a study in a general population. Neurology (2002) 1.04
A clinical scoring system highly predictive of long-term kidney graft survival. Kidney Int (2010) 1.03
Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. Arch Surg (2006) 1.02
Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol (2011) 1.02
Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft. Immunol Lett (2005) 1.02
Smoking as a precipitating factor for migraine: a survey in medical students. J Headache Pain (2009) 1.01
Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis (2010) 1.01
Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant (2005) 1.00
Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions. Nephrol Dial Transplant (2004) 1.00
Time-zero renal biopsy in living kidney transplantation: a valuable opportunity to correlate predonation clinical data with histological abnormalities. Transplantation (2008) 1.00
Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol (2011) 1.00
Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol (2003) 0.99
Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance. Nephrol Dial Transplant (2007) 0.99
Caspase-8 and caspase-3 small interfering RNA decreases ischemia/reperfusion injury to the liver in mice. Surgery (2004) 0.99
No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int (2009) 0.99
Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int (2007) 0.98
Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit (2004) 0.98
Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant (2013) 0.97
Metabolic syndrome components in patients with autosomal-dominant polycystic kidney disease. Kidney Blood Press Res (2009) 0.97
Kinetics of plasmatic cytokines and cystatin C during and after hemodialysis in septic shock-related acute renal failure. Crit Care (2010) 0.97
Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation (2003) 0.97
Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis (2007) 0.97
Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. Pharmacogenet Genomics (2012) 0.97
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet (2010) 0.96
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant (2004) 0.96
Predictive factors for posttransplant diabetes mellitus within one-year of liver transplantation. Transplantation (2008) 0.96
Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int (2007) 0.96
Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl (2006) 0.96
Graft versus host disease after liver transplantation - a single center experience and review of literature. Transpl Int (2008) 0.96
Quantitation of human cytomegalovirus in recipients of solid organ transplants by real-time quantitative PCR and pp65 antigenemia. J Med Virol (2003) 0.95
Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transpl Int (2012) 0.95
Cardiovascular and noncardiovascular mortality among men and women starting dialysis. Clin J Am Soc Nephrol (2011) 0.95